Maria Del Carmen Boyano-Adánez

Dr. Maria Del Carmen Boyano-Adánez


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2016 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
EBElena de Blas
Elena de Blas
MEMaría Cristina Estañ
María Cristina Estañ
MFMaría del Carmen Gómez de Frutos
María del Carmen Gómez de Frutos
JPJavier Ramos Paradas
Javier Ramos Paradas
MBMaria Del Carmen Boyano-Adánez
Maria Del Carmen Boyano-Adánez
PAPatricio Aller
Patricio Aller
The glycolysis inhibitor 2-deoxy-d-glucose (2-DG) is a safe, potentially useful anti-tumour drug, but its efficacy is normally low when used alone. Recent studies indicated that 2-DG stimulates the PI3K/Akt and MEK/ERK defensive pathways, which limits the apoptotic efficacy in tumour cell lines. We hypothesized that co-treatment with selected polyphenols could improve 2-DG-provoked apoptosis by preventing defensive kinase activation. Cell proliferation was measured by cell counting or the MTT assay. Cell cycle, apoptosis and necrosis were determined by propidium iodide staining and/or annexin V labeling followed by flow cytometry. Mitochondria pore transition and depolarization were determined by calcein-ATM or rhodamine 123 labeling followed flow cytometry. Intracellular reactive oxygen species and GSH were determined by dichlorodihydrofluorescein diacetate or monochlorobimane labeling followed by flow cytometry or fluorimetry. Expression and phosphorylation of protein kinases were analyzed by the Western blot. (i) 2-DG-provoked apoptosis was greatly potentiated by co-treatment with the sub-lethal concentrations of the flavonoid quercetin in human HL60 acute myeloblastic leukemia cells. Allowing for quantitative differences, apoptosis potentiation was also obtained using NB4 promyelocytic and THP-1 promonocytic cells, using curcumin or genistein instead of quercetin, and using lonidamine instead of 2-DG, but not when 2-DG was substituted by incubation in glucose-free medium. (ii) Quercetin and 2-DG rapidly elicited the opening of mitochondria pore transition, which preceded the trigger of apoptosis. (iii) Treatments did not affect GSH levels, and caused disparate effects on reactive oxygen species generation, which did not match the changes in lethality. (iv) 2-DG and lonidamine stimulated defensive Akt and ERK phosphorylation/activation, while glucose starvation was ineffective. Polyphenols prevented the stimulation of Akt phosphorylation, and in some cases also ERK phosphorylation. In addition, quercetin and 2-DG stimulated GSK-3α,β phosphorylation/inactivation, although with different isoform specificity. The use of pharmacologic inhibitors confirmed the importance of these kinase modifications for apoptosis. The present in vitro observations suggest that co-treatment with low concentrations of selected polyphenols might represent a manner of improving the poor anti-tumour efficacy of some glycolytic inhibitors, and that apoptosis potentiation may be at least in part explained by the regulation of defensive protein kinase activities.

3 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
LSLeticia Szadai
Leticia Szadai
EVErika Velasquez
Erika Velasquez
BSBeáta Szeitz
Beáta Szeitz
NANatália Pinto de Almeida
Natália Pinto de Almeida
GDGilberto Domont
Gilberto Domont
György Marko-VargaGyörgy Marko-Varga
György Marko-Varga
The discovery of novel protein biomarkers in melanoma is crucial. Our introduction of formalin-fixed paraffin-embedded (FFPE) tumor protocol provides new opportunities to understand the progression of melanoma and open the possibility to screen thousands of FFPE samples deposited in tumor biobanks and available at hospital pathology departments. In our retrospective biobank pilot study, 90 FFPE samples from 77 patients were processed. Protein quantitation was performed by high-resolution mass spectrometry and validated by histopathologic analysis. The global protein expression formed six sample clusters. Proteins such as TRAF6 and ARMC10 were upregulated in clusters with enrichment for shorter survival, and proteins such as AIFI1 were upregulated in clusters with enrichment for longer survival. The cohort’s heterogeneity was addressed by comparing primary and metastasis samples, as well comparing clinical stages. Within immunotherapy and targeted therapy subgroups, the upregulation of the VEGFA-VEGFR2 pathway, RNA splicing, increased activity of immune cells, extracellular matrix, and metabolic pathways were positively associated with patient outcome. To summarize, we were able to (i) link global protein expression profiles to survival, and they proved to be an independent prognostic indicator, as well as (ii) identify proteins that are potential predictors of a patient’s response to immunotherapy and targeted therapy, suggesting new opportunities for precision medicine developments.

Verified
Journal Article
Open access
PDF file
Miguel A. OrtegaMiguel A. Ortega
Miguel A. Ortega
LPLeonel Pekarek
Leonel Pekarek
FNFátima Navarro
Fátima Navarro
OFOscar Fraile-Martínez
Oscar Fraile-Martínez
CGCielo García-Montero
Cielo García-Montero
MAMelchor Alvarez-Mon
Melchor Alvarez-Mon
Non-small cell lung cancer (NSCLC) is the most frequent form of lung cancer and represents a set of histological entities that have an ominous long-term prognosis, for example, adenocarcinoma, squamous carcinoma and large cell carcinoma. Both small cell and non-small cell lung cancer are the main causes of oncological death and the oncological diseases with the highest incidence worldwide. With regard to clinical approaches for NSCLC, several advances have been achieved in diagnosis and treatment; the analysis of different molecular markers has led to the development of new targeted therapies that have improved the prognosis for selected patients. Despite this, most patients are diagnosed in an advanced stage, presenting a limited life expectancy with an ominous short-term prognosis. Numerous molecular alterations have been described in recent years, allowing for the development of therapies directed against specific therapeutic targets. The correct identification of the expression of different molecular markers has allowed for the individualization of treatment throughout the disease course, expanding the available therapeutic arsenal. The purpose of this article is to summarize the main characteristics of NSCLC and the advances that have occurred in the use of targeted therapies, thus explaining the limitations that have been observed in the management of this disease.

18 October 2014 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
IGI. Gañán-Gómez
I. Gañán-Gómez
MEM. C. Estañ-Omaña
M. C. Estañ-Omaña
PSP. Sancho
P. Sancho
PAP. Aller
P. Aller
MBMaria Del Carmen Boyano-Adánez
Maria Del Carmen Boyano-Adánez

1 March 2004 in Journal of Pineal Research
Verified
Journal Article
Closed access
PDF file
RIRosa Maria Izquierdo-Claros
Rosa Maria Izquierdo-Claros
MBMaria Del Carmen Boyano-Adánez
Maria Del Carmen Boyano-Adánez
EAEduardo Arilla-Ferreiro
Eduardo Arilla-Ferreiro

17 October 2002 in Journal of Pineal Research
Verified
Journal Article
Closed access
PDF file
RIRosa María Izquierdo‐Claros
Rosa María Izquierdo‐Claros
MBMaria Del Carmen Boyano-Adánez
Maria Del Carmen Boyano-Adánez
EAEduardo Arilla‐Ferreiro
Eduardo Arilla‐Ferreiro